We could not find any results for:
Make sure your spelling is correct or try broadening your search.
N -- Full year net sales for continuing operations1 up 9% (cc2, +6% USD): -- Pharmaceuticals BU growing 12% (cc) driven by Cosentyx USD 3.6 billion (+28% cc), Entresto USD 1.7 billion (+71% cc...
N -- Der Nettoumsatz der fortzuführenden Geschäftsbereiche1 steigt 2019 um 9% (kWk2, +6% USD): -- Die Geschäftseinheit Pharmaceuticals wächst um 12% (kWk), getragen von...
N -- Hausse du chiffre d'affaires net des activités poursuivies1 de 9% sur l'exercice entier (tcc2, +6% USD): -- Pharmaceuticals: cette unité opérationnelle progresse de...
N Basel, January 6, 2020 -- Novartis AG (NYSE: NVS) ("Novartis") today announced the successful completion of the previously announced tender offer by its indirect wholly-owned...
N -- Pooled analyses of LUSTER 1 and 2 did not support further development of Fevipiprant in asthma as a primary indication -- Fevipiprant was well tolerated with adverse events balanced across...
N Basel, December 5, 2019 -- Novartis AG (NYSE: NVS) ("Novartis") today announced that its indirect wholly-owned subsidiary, Medusa Merger Corporation, a Delaware corporation...
N -- Over 50 million secondary prevention patients worldwide with atherosclerotic cardiovascular disease (ASCVD) or familial hypercholesterolemia (FH) on current standard of care do not achieve...
N -- Sickle cell pain crises are unpredictable, severe events associated with life-threatening complications1 -- Adakveo reduced the annual rate of sickle cell pain crises by 45% compared to...
N -- Cosentyx narrowly missed statistical significance for superiority in ACR 20, the primary endpoint of the EXCEED trial, while showing numerically higher results versus Humira(R)*[1]...
N -- FDA placed a partial hold on AVXS-101 intrathecal clinical trials for SMA patients based on findings in a small pre-clinical animal study -- Adverse events that might be expected from the...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 76.79 | 76.79 | 76.79 | 184 | 76.79 | DE |
4 | 0 | 0 | 76.79 | 76.79 | 76.79 | 333 | 76.79 | DE |
12 | 0 | 0 | 76.79 | 76.79 | 76.79 | 2187 | 76.79 | DE |
26 | 0 | 0 | 76.79 | 76.79 | 76.79 | 3768 | 76.79 | DE |
52 | 0 | 0 | 76.79 | 76.79 | 76.79 | 9148 | 76.79 | DE |
156 | 0 | 0 | 76.79 | 76.79 | 76.79 | 21254 | 76.79 | DE |
260 | 0 | 0 | 76.79 | 76.79 | 76.79 | 18234 | 76.79 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions